Search Results

Return to List
Results 1–20 of 20
Sort By: Relevance | Date | Title
1.

Access to Emergency Contraception

Committee Opinion Number 542, November 2012

ABSTRACT Emergency contraception includes contraceptive methods used to prevent pregnancy in the first few days after unprotected intercourse sexual assault or contraceptive failure Although the US Food and Drug Administration approved the first dedicated product for emergency contraception in 199...

November 2012

PDF Format
2.

Aromatase Inhibitors in Gynecologic Practice

Committee Opinion Number 663, June 2016

(Replaces Committee Opinion Number 412, August 2008)

ABSTRACT Aromatase inhibitors have been used for the treatment of breast cancer ovulation induction endometriosis and other estrogenmodulated conditions For women with breast cancer bone mineral density screening is recommended with longterm aromatase inhibitor use because of risk of osteoporosis ...

June 2016

PDF Format
3.

Brand Versus Generic Oral Contraceptives

Committee Opinion Number 375, August 2007

(Reaffirmed 2015)

ABSTRACT The US Food and Drug Administration considers generic and brand name oral contraceptive OC products clinically equivalent and interchangeable The American College of Obstetricians and Gynecologists supports patient or clinician requests for branded OCs or continuation of the same generic ...

August 2007

PDF Format
4.

Chronic Antithrombotic Therapy and Gynecologic Surgery

Committee Opinion Number 610, October 2014

ABSTRACT Surgery can present a management dilemma for gynecologists whose patients receive chronic antithrombotic therapy because the risk of hemorrhagic complications must be balanced against the risk of thromboembolic complications Interruption of antithrombotic therapy to reduce perioperative b...

October 2014

PDF Format
5.

Compounded Bioidentical Menopausal Hormone Therapy

Committee Opinion Number 532, August 2012

(Reaffirmed 2016, Replaces No. 387, November 2007 and No. 322, November 2005)

ABSTRACT Although improvement in longterm health is no longer an indication for menopausal hormone therapy evidence supporting fewer adverse events in younger women combined with its high overall effectiveness has reinforced its usefulness for shortterm treatment of menopausal symptoms Menopausal ...

August 2012

PDF Format
6.

Ethical Issues With Vaccination for the Obstetrician–Gynecologist

Committee Opinion Number 564, May 2013

(Reaffirmed 2016)

ABSTRACT Because of the growing importance of infectious disease prevention in the individual patient and the larger community it is vital that Fellows of the American College of Obstetricians and Gynecologists be prepared to navigate the practical and ethical challenges that come with vaccination...

May 2013

PDF Format
7.

Integrating Immunizations Into Practice

Committee Opinion Number 661, April 2016

ABSTRACT Immunization against vaccinepreventable diseases is an essential component of womens primary and preventive health care Despite the importance of vaccination and clear guidance from public health agencies rates of vaccination lag behind national goals Obstetriciangynecologists can play a ...

April 2016

PDF Format
8.

Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged Women

Committee Opinion Number 557, April 2013

(Reaffirmed 2015)

ABSTRACT Initial evaluation of the patient with acute abnormal uterine bleeding should include a prompt assessment for signs of hypovolemia and potential hemodynamic instability After initial assessment and stabilization the etiologies of acute abnormal uterine bleeding should be classified using ...

April 2013

PDF Format
9.

Misoprostol for Postabortion Care

Committee Opinion Number 427, February 2009

ABSTRACT The World Health Organization estimates that 67000 women mostly in developing countries die each year from untreated or inadequately treated abortion complications Postabortion care a term commonly used by the international reproductive health community refers to a specific set of service...

February 2009

PDF Format
10.

OnabotulinumtoxinA and the Bladder

Committee Opinion Number 604, June 2014

ABSTRACT In January 2013 the US Food and Drug Administration approved the use of onabotulinumtoxinA also known as Botox A for the treatment of overactive bladder thus providing another treatment option for women Symptoms of overactive bladder have been shown to significantly improve after onabotul...

June 2014

PDF Format
11.

Options for Prevention and Management of Heavy Menstrual Bleeding in Adolescent Patients Undergoing

Committee Opinion Number 606, August 2014

(Reaffirmed 2016)

ABSTRACT Adolescents undergoing cancer treatment are at high risk of heavy menstrual bleeding and gynecologists may be consulted either before the initiation of cancer treatment to request strategies for menstrual suppression or during an episode of severe heavy bleeding to stop the bleeding emerg...

August 2014

PDF Format
12.

Ovarian Reserve Testing

Committee Opinion Number 618, January 2015

ABSTRACT The main goal of ovarian reserve testing is to identify those individuals who are at risk of decreased or diminished ovarian reserve commonly known as DOR Although ovarian reserve testing cannot predict the end of ones reproductive years results outside the range expected for a patients a...

January 2015

PDF Format
13.

Over-the-Counter Access to Oral Contraceptives

Committee Opinion Number 544, December 2012

(Reaffirmed 2016)

ABSTRACT Unintended pregnancy remains a major public health problem in the United States Access and cost issues are common reasons why women either do not use contraception or have gaps in use A potential way to improve contraceptive access and use and possibly decrease unintended pregnancy rates ...

December 2012

PDF Format
14.

Postmenopausal Estrogen Therapy: Route of Administration and Risk of Venous Thromboembolism

Committee Opinion Number 556, April 2013

(Reaffirmed 2015)

ABSTRACT The development of menopausal symptoms and related disorders which lead women to seek prescriptions for postmenopausal estrogen therapy and hormone therapy is a common reason for a patient to visit her gynecologist but these therapies are associated with an increased risk of venous thromb...

April 2013

PDF Format
15.

Preexposure Prophylaxis for the Prevention of Human Immunodeficiency Virus

Committee Opinion Number 595, May 2014

Abstract Preexposure prophylaxis is defined as the administration of antiretroviral medications to individuals who are not infected with human immunodeficiency virus HIV and are at the highest risk of acquiring HIV infection In combination with other proven HIVprevention methods preexposure prophy...

May 2014

PDF Format
16.

Primary Ovarian Insufficiency in Adolescents and Young Women

Committee Opinion Number 605, July 2014

(Reaffirmed 2016)

ABSTRACT Primary ovarian insufficiency is the depletion or dysfunction of ovarian follicles with cessation of menses before age 40 years There is no consensus on criteria to identify primary ovarian insufficiency in adolescents and delay in diagnosis is common Health care providers who make this c...

July 2014

PDF Format
17.

Risk of Venous Thromboembolism Among Users of Drospirenone-Containing Oral Contraceptive Pills

Committee Opinion Number 540, November 2012

(Reaffirmed 2016)

ABSTRACT Although the risk of venous thromboembolism is increased among oral contraceptive users compared with nonusers who are not pregnant and not taking hormones and some data have suggested that use of drospirenonecontaining pills has a higher risk of venous thromboembolism this risk is still ...

November 2012

PDF Format
18.

Solutions for Surgical Preparation of the Vagina

Committee Opinion Number 571, September 2013

(Reaffirmed 2015)

ABSTRACT Currently only povidoneiodine preparations are approved for vaginal surgicalsite antisepsis However there are compelling reasons to consider chlorhexidine gluconate solutions for offlabel use in surgical preparation of the vagina especially in women with allergies to iodine Although chlor...

September 2013

PDF Format
19.

Tamoxifen and Uterine Cancer

Committee Opinion Number 601, June 2014

(Replaces Committee Opinion Number 336, June 2006)

ABSTRACT Tamoxifen a nonsteroidal antiestrogen agent is widely used as adjunctive therapy for women with breast cancer and it has been approved by the US Food and Drug Administration for adjuvant treatment of breast cancer treatment of metastatic breast cancer and reduction in breast cancer incide...

June 2014

PDF Format
20.

The Use of Vaginal Estrogen in Women With a History of Estrogen-Dependent Breast Cancer

Committee Opinion Number 659, March 2016

ABSTRACT Cancer treatment should address femalespecific survivorship issues including the hypoestrogenicrelated adverse effects of cancer therapies or of natural menopause in survivors Systemic and vaginal estrogen are widely used for symptomatic relief of vasomotor symptoms sexual dysfunction and...

March 2016

PDF Format

American Congress of Obstetricians and Gynecologists
409 12th Street SW, Washington, DC  20024-2188 | Mailing Address: PO Box 70620, Washington, DC 20024-9998